Is Retatrutide Legal? FDA, Compounding and WADA Status
Retatrutide's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.
- FDA status
- Not approved
- Investigational · phase 3
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Prohibited (S0)
- In and out of competition
Current status
Investigational · phase 3No. Retatrutide is investigational (investigational · phase 3) and not approved for any use.
| Country | Status | Source |
|---|---|---|
| United States | No approved product foundNo FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "retatrutide" returned no matches on 2 Oct 2026. | api.fda.govchecked 2 Oct 2026 |
Timeline
- Retatrutide phase 3 TRIUMPH-1 results publishedTrial
- FDA warning letters to five research-peptide sellersEnforcement
- Eli Lilly sues six retatrutide sellersOther
- Seven FDA warning letters to online sellers of GLP-1 productsEnforcement
Compounding and research-use sellers
- Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
- The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
- "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.
Sport and drug testing
Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.
Outside the US
Rules differ by country. What each regulator's own records show, with the date we checked:
| Country | Status | Source |
|---|---|---|
| United Kingdom | No approved product foundNo approved product found in an emc (UK SmPC compendium) search for "retatrutide" on 2 Oct 2026. | medicines.org.ukchecked 2 Oct 2026 |
| Canada | No approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "retatrutide" on 2 Oct 2026. | health-products.canada.cachecked 2 Oct 2026 |
| Australia | No approved product foundNo approved product found in an ARTG search for "retatrutide" on 2 Oct 2026. | tga.gov.auchecked 2 Oct 2026 |
| European Union | No centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026 | ema.europa.euchecked 2 Oct 2026 |
Can retatrutide be compounded? FDA says no
FDA's GLP-1 page rules out pharmacy compounding of retatrutide: federal law does not allow it, and the agency adds that the drug is not part of any approved medicine.[15]
The same page lists the parties FDA has warned over retatrutide: telehealth firms marketing it directly to consumers, ingredient distributors supplying compounders, and outsourcing facilities repackaging it.[15]
Retatrutide has a published phase 3 but no approval record
Drugs@FDA returns no match for retatrutide, so no FDA-approved retatrutide product exists in that database.[4]
The first phase 3 result, TRIUMPH-1, appeared online in the New England Journal of Medicine on 2026 Sep 29: adults with obesity without diabetes, once-weekly 4, 9 or 12 mg against placebo for 80 weeks, 2339 randomized.[1]
The EMA export, the Health Canada database and the UK compendium search each found nothing for retatrutide.[8]
Enforcement aimed at retatrutide sellers in 2026
In its March warning letter to an online seller, FDA reproduced the seller’s own retatrutide product copy as evidence of drug claims, and noted the seller’s “Research Use Only” labelling did not change the human-use intent.[16]
That letter went on to treat the seller’s bacteriostatic water as a drug too, since it was sold next to injectable peptides.[16]
Retatrutide was named again in the August letters. One of them quoted a seller describing it as a triple receptor agonist and “glp3 peptide”.[17]
On August 12, 2026 the developer, Eli Lilly, announced new lawsuits against U.S. entities selling retatrutide products and said it referred more than 200 individuals and entities to regulators.[13]
Is retatrutide banned in sport? WADA's S0 rule
WADA’s route to retatrutide is the S0 catch-all for substances still in development, so approval anywhere would change its status.[3]
PeptideDeck, our sister site, keeps a separate guide on where to buy retatrutide.
Common questions
Is retatrutide FDA approved?
No. FDA’s database has no retatrutide product, and the TRIUMPH-1 publication dated 2026 Sep 29 is a trial report, not an approval.[1]
Is Retatrutide legal to buy?
FDA has warned firms that sold retatrutide products labelled for research purposes, and it urges consumers not to buy them because their quality is unknown. Its separate position is that retatrutide cannot be compounded under federal law.[15]
Is Retatrutide banned by WADA?
Yes. Prohibited by WADA (S0), in and out of competition.
Retatrutide FDA approval: when?
No date appears in the FDA records collected here. The phase 3 results that would support an application were still being published as of 2026 Sep 29.[1]
Is retatrutide legal?
Selling it for human use is what FDA’s warning letters treat as unlawful: with no approved application in effect, FDA calls such products unapproved new drugs.[16]
Retatrutide release date?
No release date appears in the regulatory record. The dated items are a trial publication, enforcement letters and litigation.[13]
Is retatrutide legal in the US?
In FDA's view, a retatrutide product sold for human use is an unapproved new drug, because no approved application covers it. This page does not cover rules on personal possession.[18]
Does 'research use only' make retatrutide legal to sell?
No. FDA has warned sellers whose retatrutide-containing products carried a research or not-for-human-consumption label while being sold to consumers for human use.[15]
More on Retatrutide
Sources
- 1Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
- 2Warning letter to NuScience Peptides LLC (ref. 733652), 24 Aug 2026, one of five letters to research-peptide sellers issued that dayU.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "retatrutide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 5United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "retatrutide" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
- 6Canada: No product found in a Health Canada Drug Product Database search for ingredient "retatrutide" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 7Australia: No approved product found in an ARTG search for "retatrutide" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
- 8EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
- 9World Anti-Doping Code: Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 10Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 11Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 13Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 14Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 15Official web pageOfficial web page · web page
- 16Official web pageOfficial web page · web page
- 17Official web pageOfficial web page · web page
- 18Official web pageOfficial web page · web page
Found an error? Report a correction.